Press Release - Vertex Pharmaceuticals Newsroom
WEBDec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
Newsroom | Vertex Pharmaceuticals Newsroom
WEBJul 02 2024. Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis. Read More.
Vertex Announces Positive Results From Phase 2 Study of VX-548 …
WEBBOSTON, December 13, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in...
News & Events - Vertex Pharmaceuticals
WEBJan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the …
News & Events - Vertex Pharmaceuticals
WEBJan 7, 2024 · Epidemiology update: Vertex revised its estimates for the number of patients living with cystic fibrosis from ~88,000 to ~92,000 in the U.S., Europe, Australia, and Canada. Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) – …
Vertex Pharmaceuticals Incorporated (VRTX) Latest Stock News ...
WEBGet the latest Vertex Pharmaceuticals Incorporated (VRTX) stock news and headlines to help you in your trading and investing decisions.
Press Release - Vertex Pharmaceuticals Newsroom
WEBJun 21, 2024 · At the latest visit, all patients had improved glycemic control and achieved ADA -recommended targets for both HbA1c below 7.0% and time-in-range above 70% on continuous glucose monitoring. Nearly all participants (11 of 12) had a reduction or elimination of exogenous insulin use at their last visit.
News & Events - Vertex Pharmaceuticals
WEBJul 30, 2024 · Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years. The FDA has granted suzetrigine priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025.
Vertex's non-opioid drug reduces nerve pain in trial, shares hit …
WEBDec 13 (Reuters) - Vertex Pharmaceuticals' (VRTX.O) non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling...
Vertex Pharmaceuticals | Home
WEBFeatured Stories. Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Skip to content